Neurologic Symptoms as a Feature of the Antiphospholipid Syndrome

ABSTRACT

Antiphospholipid antibodies may cause various neurologic diseases by vascular and immune mechanisms. Ischemic stroke and transient ischemic attacks are the most common neurologic complications in patients with antiphospholipid antibodies but migraine, epilepsy, chorea, or multiple sclerosis also may occur. Although the neurologic presentation of patients with the antiphospholipid syndrome may vary, many patients have striking similarities, such as initial memory loss, aphasia, cognitive dysfunction with progressive cerebral deterioration, and even dementia. In conclusion, antiphospholipid syndrome may constitute a treatable cause of neurologic diseases, and the measurement of antiphospholipid antibodies should be routinely performed in patients with neurologic disorders.

Stroke - neurologic - antiphospholipid syndrome - epilepsy

REFERENCES

• 1 Miyakis S, Lockshin M D, Atsumi T et al.. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome.  J Thromb Haemost. 2006;  4 295-306
• 2 Harris E N, Gharavi A E, Asherson R A et al.. Cerebral infarction in systemic lupus: association with anticardiolipin antibodies.  Clin Exp Rheumatol. 1984;  2 47-51
• 3 Ferro D, Quintarelli C, Rasura M et al.. Lupus anticoagulant and the fibrinolytic system in young patients with stroke.  Stroke. 1993;  24 368-370
• 4 Tietjen G E, Levine S R, Brown E et al.. Factors that predict antiphospholipid immunoreactivity in young people with transient focal neurological events.  Arch Neurol. 1993;  50 833-836
• 5 Anticardiolipin antibodies are an independent risk factor for first ischemic stroke. The antiphospholipid antibodies in stroke study (APASS) group.  Neurology. 1993;  43 2069-2073
• 6 Muir K W, Squire I B, Alwan W et al.. Anticardiolipin antibodies in an unselected stroke population.  Lancet. 1994;  344 452-456
• 7 Munoz-Rodriguez F J, Font J, Cervera R et al.. Clinical study and follow-up of 100 patients with antiphospholipid syndrome.  Semin Arthritis Rheum. 1999;  29 182-189
• 8 Sanna G, Bertolaccini M L, Cuadrado M J et al.. Neuropsychiatric manifestations in systemic lupus erythematosus: prevelance and association with antiphospholipid antibodies.  J Rheumatol. 2003;  30 985-992
• 9 Janardhan V, Wolf P A, Kase C S et al.. Anticardiolipin antibodies and risk of ischemic stroke and transient ischemic attack. The Framingham cohort and offspring study.  Stroke. 2004;  35 736-741
• 10 Jara L J, Medina G, Vera-Lastra O et al.. Atherosclerosis and antiphospholipid syndrome.  Clin Rev Allergy Immunol. 2003;  25 79-88
• 11 Medina G, Casaos D, Jara L J et al.. Increased carotid artery intima-media thickness may be associated with stroke in primary antiphospholipid syndrome.  Ann Rheum Dis. 2003;  62 607-610
• 12 Levine S R, Brey R L, Sawaya K L et al.. Recurrent stroke and thrombo-occlusive events in the antiphospholipid syndrome.  Ann Neurol. 1995;  38 119-124
• 13 Miesbach W, Gilzinger A, Gökpinar B et al.. Prevalence of antiphospholipid antibodies in patients with neurological symptoms.  Clin Neurol Neurosurg. 2006;  108 135-142
• 14 Tietjen G E, Day M, Norris L et al.. Role of anticardiolipin antibodies in young persons with migraine and transient neurological events.  Neurology. 1998;  50 1433-1440
• 15 Silvestrini M, Matteis M, Troisi E et al.. Migrainous stroke and the antiphospholipid antibodies.  Eur Neurol. 1994;  34 316-319
• 16 Carhuapoma J R, Mitsia P, Levine S R. Cerebral venous thrombosis and anticardiolipin antibodies.  Stroke. 1997;  28 2363-2369
• 17 Cuadrado M J, Khamashta M A, Ballesteros A et al.. Can neurologic manifestations of Hughes (antiphospholipid) syndrome be distinguished from multiple sclerosis? Analysis of 27 patients and review of the literature.  Medicine. 2000;  79 57-68
• 18 Chapman J, Cohen-Armin M, Shoenfeld Y et al.. Antiphospholipid antibodies permeabilize and depolarize brain synaptoneurosomes.  Lupus. 1999;  8 127-133
• 19 Shoenfeld Y, Lev S, Blatt I et al.. Features associated with epilepsy in the antiphospholipid syndrome.  J Rheumatol. 2004;  31 1344-1348
• 20 Cimaz R, Meroni P L, Shoenfeld Y. Epilepsy as part of systemic lupus erythematosus and systemic antiphospholipid syndrome (Hughes syndrome).  Lupus. 2006;  15 191-197
• 21 Asherson R A, Derksen R H, Harris E N et al.. Chorea in systemic lupus erythematosus and “lupus-like” disease: association with antiphospholipid antibodies.  Semin Arthritis Rheum. 1987;  16 253-259
• 22 Cervera R, Asherson R A, Font J et al.. Chorea in the antiphospholipid syndrome. Clinical, radiologic, and immunologic characteristics of 50 patients from our clinics and the recent literature.  Medicine. 1997;  76 203-212
• 23 Asherson R A, Mercey D, Phillips G et al.. Recurrent stroke and multi-infarct dementia in systemic lupus erythematosus: association with antiphospholipid antibodies.  Ann Rheum Dis. 1987;  46 605-611
• 24 Hanly J G, Hong C, Smith S et al.. A prospective analysis of cognitive function and anticardiolipin antibodies in systemic lupus erythematosus.  Arthritis Rheum. 1999;  42 728-734
• 25 Menon S, Jameson-Shortall E, Newman S P et al.. A longitudinal study of anticardiolipin antibody levels and cognitive functioning in systemic lupus erythematosus.  Arthritis Rheum. 1999;  42 735-741
• 26 Schmidt R, Auer-Grumbach P, Fazekas F et al.. Anticardiolipin antibodies in normal subjects. Neuropsychological correlates and MRI findings.  Stroke. 1995;  26 749-754
• 27 Inzelberg R, Bornstein N M, Reider I et al.. The lupus anticoagulant and dementia in non-SLE patients.  Dementia. 1992;  3 140-145
• 28 Levine S R, Salowich-Palm L, Sawaya K L et al.. IgG anticardiolipin antibody titer > 40 GPL and the risk of subsequent thrombo-occlusive events and death. A prospective cohort study.  Stroke. 1997;  28 1660-1665
• 29 Nomura H, Hirashima Y, Endo S et al.. Anticardiolipin antibody aggravates cerebral vasospasm after subarachnoid hemorrhage in rabbits.  Stroke. 1998;  29 1014-1018
• 30 Levine S R, Brey R L. Neurological aspects of antiphospholipid antibody syndrome.  Lupus. 1996;  5 347-353
• 31 Caronti B, Calderaro C, Alessandri C et al.. Serum anti-β2-glycoprotein I antibodies from patients with antiphospholipid antibody syndrome bind central nervous system cells.  J Autoimmun. 1998;  11 425-429
• 32 Ziporen L, Shoenfeld Y, Levy Y et al.. Neurological dysfunction and hyperactive behavior associated with antiphospholipid antibodies.  J Clin Invest. 1997;  100 613-619
• 33 Kent M N, Alvarez F J, Ng A K, Rote N S. Ultrastructural localization of monoclonal antiphospholipid antibody binding to rat brain.  Exp Neurol. 2000;  163 173-179